VV ECMO in ARDS Patients Post-Hematopoietic Stem Cell Transplant (HSCT)

Background

  • Advances in hematological disease treatment: HSCT, CAR-T, biologics → improved prognosis.

  • Simultaneous progress in critical care & ARDS management (ARDSNet strategies, fluid restriction, transfusion reduction).

  • Despite progress, subset of patients develop refractory hypoxemia/hypercapnia → ECMO considered.

  • Fragile population: increased risks of bleeding, infection, neutropenia, organ dysfunction, altered drug kinetics.

Mortality & Prognosis

  • Historically, ICU mortality for HSCT patients with ARDS very high (58–70%).

  • Since 2010, outcomes improved with aggressive ICU support.

  • Large Franco-Belgian multicenter study (>1,000 patients):

    • Early ICU admission strongly linked to survival.

    • Survivors at hospital discharge had ~100% 24-month survival.

  • Prognosis worse after allogeneic vs autologous transplant (higher infection/sepsis risk).

  • 1-year mortality post-allogeneic HSCT still ~67%.

Recent Evidence

  • Long-term mortality remains high, especially with prolonged ICU stay (>28 days), multiple organ support, or vasopressor use.

  • Studies show outcomes depend on:

    • Type of transplant (autologous > allogeneic).

    • Timing of respiratory failure (early graft dysfunction = poor prognosis).

    • Underlying disease remission vs relapse.

    • Number of organ failures (multi-organ failure = poor candidate).

ECMO-Specific Considerations

  • Patient selection is critical: avoid cases with uncertain prognosis, graft failure, uncontrolled infections, GVHD.

  • Indications/criteria:

    • Refractory hypoxemia (PaO₂/FiO₂ < 60 for >3h).

    • Mechanical ventilation ≤7 days.

    • Severe respiratory failure despite optimal care.

  • Contraindications/poor candidates:

    • Early graft dysfunction, severe GVHD, uncontrolled fungal infection, multi-organ failure.

  • Complications:

    • Higher bleeding risk (low platelets, anticoagulation).

    • ECMO may worsen immunosuppression/infections.

    • Drug absorption/PK during ECMO not fully understood, esp. chemotherapy.

Key Studies

  • 2014 (Wal et al.): first uniform series (14 hematological patients on ECMO) → feasible, survival possible in selected patients.

  • 2022 (Kak et al.): highlighted prognostic “red flags”: low platelets, high lactate, progressive disease.

  • Position papers (ELSO/EuroELSO, oncology experts) → 36 statements guiding ECMO in HSCT/oncology; most reached strong consensus.

Practical & Ethical Lessons

  • Multidisciplinary decision-making essential (ICU, oncology, hematology, nephrology, infectious disease).

  • Involve family and patients early, ensure realistic expectations.

  • Consider financial/resource implications.

  • Use scores (RESP, PRESERVE) but weigh heavily immunosuppressed status.

  • Anticoagulation: heparin standard; bivalirudin increasingly used. Platelet transfusion thresholds lower (≥20k often accepted).

  • Focus on neurological/functional recovery & quality of life, not just hospital discharge.

Take-Home Messages

  • VV ECMO can be life-saving in carefully selected HSCT patients with ARDS.

  • Outcomes hinge on:

    • Patient selection.

    • Early intervention.

    • Minimizing complications (bleeding, infection).

    • Institutional expertise and resources.

  • ECMO should be considered rescue therapy, not routine, in this fragile population.

  • Goal: meaningful long-term survival with good neurological and functional recovery, not just survival to ICU discharge.

PreviousNext